The lone approved asset in Dendreon's portfolio was cancer immunotherapy Provenge ... than Valeant Pharmaceuticals When …
Hedge fund
Dendreon (DNDN) stock opened slightly higher this morning, despite the fact that Dendreon earnings for Q3 rolled in even worse than expected. Product revenue for DNDN — which is to say revenue from its only …
Dendreon Corporation (DNDN) stock is down about 64% during premarket trade today, after the company announced it had reached an agreement with bondholders for a financial restructure and filed for Chapter 11 …
Barclays analyst Douglas Tsao stated, “After the successful sale of …
Earnings
Since Dendreon's (NASDAQ:DNDN) conference call on April 13 to announce that the Provenge Phase III IMPACT clinical trial easily met its primary endpoint of a 22% reduction in deaths versus the placebo group, there have …
NASDAQ
NEW YORK An experimental medicine from Dendreon Corp improved survival in men with advanced forms of prostate cancer, the company said on Tuesday, bolstering chances of it becoming the first approved …
Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.92% of the float is sold short, suggesting …
BOSTON (MarketWatch) — Dendreon Corp.’s recent tepid sales report has not only chilled trading in the company’s once-hot stock but also managed to frost investors in three biotechs in the middle of highly …
In a nano-second, Dendreon went from obscurity to savior. Investors holding Dendreon stock suddenly found themselves instant millionaires. Dendreon is an excellent example of how a stock can shock the market, or …
Biotechnology
Dendreon, the maker of Provenge will be sold to China’s Sanpower ...
Trump